Literature DB >> 31858384

A Computational Statistics Approach to Evaluate Blood Biomarkers for Breast Cancer Risk Stratification.

Kaan Oktay1, Ashlie Santaliz-Casiano2, Meera Patel3, Natascia Marino3,4, Anna Maria V Storniolo3,4, Hamdi Torun5, Burak Acar1, Zeynep Madak Erdogan6,7,8,9,10,11.   

Abstract

Breast cancer is the second leading cause of cancer mortality among women. Mammography and tumor biopsy followed by histopathological analysis are the current methods to diagnose breast cancer. Mammography does not detect all breast tumor subtypes, especially those that arise in younger women or women with dense breast tissue, and are more aggressive. There is an urgent need to find circulating prognostic molecules and liquid biopsy methods for breast cancer diagnosis and reducing the mortality rate. In this study, we systematically evaluated metabolites and proteins in blood to develop a pipeline to identify potential circulating biomarkers for breast cancer risk. Our aim is to identify a group of molecules to be used in the design of portable and low-cost biomarker detection devices. We obtained plasma samples from women who are cancer free (healthy) and women who were cancer free at the time of blood collection but developed breast cancer later (susceptible). We extracted potential prognostic biomarkers for breast cancer risk from plasma metabolomics and proteomics data using statistical and discriminative power analyses. We pre-processed the data to ensure the quality of subsequent analyses, and used two main feature selection methods to determine the importance of each molecule. After further feature elimination based on pairwise dependencies, we measured the performance of logistic regression classifier on the remaining molecules and compared their biological relevance. We identified six signatures that predicted breast cancer risk with different specificity and selectivity. The best performing signature had 13 factors. We validated the difference in level of one of the biomarkers, SCF/KITLG, in plasma from healthy and susceptible individuals. These biomarkers will be used to develop low-cost liquid biopsy methods toward early identification of breast cancer risk and hence decreased mortality. Our findings provide the knowledge basis needed to proceed in this direction.

Entities:  

Keywords:  Breast cancer risk; Circulating biomarker; Feature selection; Liquid biopsy; Machine learning

Mesh:

Substances:

Year:  2019        PMID: 31858384     DOI: 10.1007/s12672-019-00372-3

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  38 in total

1.  Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters.

Authors:  Maria Dalamaga; George Sotiropoulos; Konstantinos Karmaniolas; Nicolaos Pelekanos; Evangelia Papadavid; Antigoni Lekka
Journal:  Clin Biochem       Date:  2013-01-13       Impact factor: 3.281

2.  Coexpression of the c-kit and stem cell factor genes in breast carcinomas.

Authors:  S J Hines; C Organ; M J Kornstein; G W Krystal
Journal:  Cell Growth Differ       Date:  1995-06

3.  Cancer biomarker discovery and validation.

Authors:  Nicolas Goossens; Shigeki Nakagawa; Xiaochen Sun; Yujin Hoshida
Journal:  Transl Cancer Res       Date:  2015-06       Impact factor: 1.241

4.  Cancer survival in five continents: a worldwide population-based study (CONCORD).

Authors:  Michel P Coleman; Manuela Quaresma; Franco Berrino; Jean-Michel Lutz; Roberta De Angelis; Riccardo Capocaccia; Paolo Baili; Bernard Rachet; Gemma Gatta; Timo Hakulinen; Andrea Micheli; Milena Sant; Hannah K Weir; J Mark Elwood; Hideaki Tsukuma; Sergio Koifman; Gulnar Azevedo E Silva; Silvia Francisci; Mariano Santaquilani; Arduino Verdecchia; Hans H Storm; John L Young
Journal:  Lancet Oncol       Date:  2008-07-17       Impact factor: 41.316

5.  Resistin, visfatin, adiponectin, and leptin: risk of breast cancer in pre- and postmenopausal saudi females and their possible diagnostic and predictive implications as novel biomarkers.

Authors:  Adel M A Assiri; Hala F M Kamel; Mohamed F R Hassanien
Journal:  Dis Markers       Date:  2015-03-08       Impact factor: 3.434

6.  Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells.

Authors:  Mateusz Opyrchal; Malgorzata Gil; Jeffrey L Salisbury; Mathew P Goetz; Vera Suman; Amy Degnim; James McCubrey; Tufia Haddad; Ianko Iankov; Chenye B Kurokawa; Nicole Shumacher; James N Ingle; Evanthia Galanis; Antonino B D'Assoro
Journal:  Oncotarget       Date:  2017-09-01

7.  Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival.

Authors:  S J Dawson; S W Duffy; F M Blows; K E Driver; E Provenzano; J LeQuesne; D C Greenberg; P Pharoah; C Caldas; G C Wishart
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

8.  Detection and localization of surgically resectable cancers with a multi-analyte blood test.

Authors:  Joshua D Cohen; Lu Li; Yuxuan Wang; Christopher Thoburn; Bahman Afsari; Ludmila Danilova; Christopher Douville; Ammar A Javed; Fay Wong; Austin Mattox; Ralph H Hruban; Christopher L Wolfgang; Michael G Goggins; Marco Dal Molin; Tian-Li Wang; Richard Roden; Alison P Klein; Janine Ptak; Lisa Dobbyn; Joy Schaefer; Natalie Silliman; Maria Popoli; Joshua T Vogelstein; James D Browne; Robert E Schoen; Randall E Brand; Jeanne Tie; Peter Gibbs; Hui-Li Wong; Aaron S Mansfield; Jin Jen; Samir M Hanash; Massimo Falconi; Peter J Allen; Shibin Zhou; Chetan Bettegowda; Luis A Diaz; Cristian Tomasetti; Kenneth W Kinzler; Bert Vogelstein; Anne Marie Lennon; Nickolas Papadopoulos
Journal:  Science       Date:  2018-01-18       Impact factor: 47.728

9.  CXCL17 expression by tumor cells recruits CD11b+Gr1 high F4/80- cells and promotes tumor progression.

Authors:  Aya Matsui; Hideaki Yokoo; Yoichi Negishi; Yoko Endo-Takahashi; Nicole A L Chun; Ichiro Kadouchi; Ryo Suzuki; Kazuo Maruyama; Yukihiko Aramaki; Kentaro Semba; Eiji Kobayashi; Masafumi Takahashi; Takashi Murakami
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

10.  Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors.

Authors:  Ge Zhang; Makito Miyake; Adrienne Lawton; Steve Goodison; Charles J Rosser
Journal:  BMC Cancer       Date:  2014-05-03       Impact factor: 4.430

View more
  13 in total

1.  TAp63 regulates bone remodeling by modulating the expression of TNFRSF11B/Osteoprotegerin.

Authors:  Anna Maria Lena; Erica Foffi; Massimiliano Agostini; Mara Mancini; Margherita Annicchiarico-Petruzzelli; Daniel Aberdam; Tania Velletri; Yufang Shi; Gerry Melino; Ying Wang; Eleonora Candi
Journal:  Cell Cycle       Date:  2021-11-11       Impact factor: 4.534

Review 2.  Recent advances in cancer immunotherapy.

Authors:  Qiang Sun; Gerry Melino; Ivano Amelio; Jingting Jiang; Ying Wang; Yufang Shi
Journal:  Discov Oncol       Date:  2021-08-18

3.  Identification of early liver toxicity gene biomarkers using comparative supervised machine learning.

Authors:  Brandi Patrice Smith; Loretta Sue Auvil; Michael Welge; Colleen Bannon Bushell; Rohit Bhargava; Navin Elango; Kamin Johnson; Zeynep Madak-Erdogan
Journal:  Sci Rep       Date:  2020-11-05       Impact factor: 4.379

Review 4.  Liquid biopsies and cancer omics.

Authors:  Ivano Amelio; Riccardo Bertolo; Pierluigi Bove; Oreste Claudio Buonomo; Eleonora Candi; Marcello Chiocchi; Chiara Cipriani; Nicola Di Daniele; Carlo Ganini; Hartmut Juhl; Alessandro Mauriello; Carla Marani; John Marshall; Manuela Montanaro; Giampiero Palmieri; Mauro Piacentini; Giuseppe Sica; Manfredi Tesauro; Valentina Rovella; Giuseppe Tisone; Yufang Shi; Ying Wang; Gerry Melino
Journal:  Cell Death Discov       Date:  2020-11-26

5.  An In Vitro Model of Mast Cell Recruitment and Activation by Breast Cancer Cells Supports Anti-Tumoral Responses.

Authors:  Angélica Aponte-López; Jennifer Enciso; Samira Muñoz-Cruz; Ezequiel M Fuentes-Pananá
Journal:  Int J Mol Sci       Date:  2020-07-26       Impact factor: 5.923

Review 6.  Serine and one-carbon metabolisms bring new therapeutic venues in prostate cancer.

Authors:  Carlo Ganini; Ivano Amelio; Riccardo Bertolo; Eleonora Candi; Angela Cappello; Chiara Cipriani; Alessandro Mauriello; Carla Marani; Gerry Melino; Manuela Montanaro; Maria Emanuela Natale; Giuseppe Tisone; Yufang Shi; Ying Wang; Pierluigi Bove
Journal:  Discov Oncol       Date:  2021-10-27

Review 7.  Central vascular ligation and mesentery based abdominal surgery.

Authors:  M Franceschilli; D Vinci; S Di Carlo; B Sensi; L Siragusa; A Guida; P Rossi; V Bellato; R Caronna; S Sibio
Journal:  Discov Oncol       Date:  2021-08-06

8.  Identification of Circulating Diagnostic Biomarkers for Coronary Microvascular Disease in Postmenopausal Women Using Machine-Learning Techniques.

Authors:  Alicia Arredondo Eve; Elif Tunc; Yu-Jeh Liu; Saumya Agrawal; Huriye Erbak Yilmaz; Sadık Volkan Emren; Filiz Akyıldız Akçay; Luidmila Mainzer; Justina Žurauskienė; Zeynep Madak Erdogan
Journal:  Metabolites       Date:  2021-05-25

9.  NUAK2 and RCan2 participate in the p53 mutant pro-tumorigenic network.

Authors:  Eleonora Mammarella; Carlotta Zampieri; Emanuele Panatta; Gerry Melino; Ivano Amelio
Journal:  Biol Direct       Date:  2021-08-04       Impact factor: 4.540

10.  Understanding p53 tumour suppressor network.

Authors:  Emanuele Panatta; Carlotta Zampieri; Gerry Melino; Ivano Amelio
Journal:  Biol Direct       Date:  2021-08-06       Impact factor: 4.540

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.